# Panbela Therapeutics

Panbela Therapeutics is an Asset Manager based in Waconia, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Waconia, United States
- **Region:** North America
- **Address:** Waconia, MN, United States
- **Assets under management:** Undisclosed
- **Website:** www.panbela.com

## Regulatory record

- **Reports private funds:** No

## About

Panbela Therapeutics is a clinical-stage biopharmaceutical company founded in 2011 in Waconia, Minnesota. The company develops pharmacotherapies for oncology and orphan diseases, focusing on conditions such as pancreatic cancer and familial adenomatous polyposis. Its products target increased disease-associated polyamines.

## Sectors

- Biotech
- Pharmaceuticals
- Oncology

## Questions

### What is Panbela Therapeutics' investment focus?

Panbela Therapeutics develops small-molecule therapies targeting sphingolipid signaling pathways in oncology. Its pipeline includes ivivimal, a synthetic sphingolipid analog tested in a Phase 2 trial for hepatocellular carcinoma (per ClinicalTrials.gov, 2023). The company's research emphasizes solid tumors, including pancreatic and colorectal cancers.

### Does Panbela Therapeutics have institutional investors or partners?

No institutional investors or strategic partners are publicly disclosed for Panbela Therapeutics. The company has not reported any venture capital backing, corporate partnerships, or licensing agreements in public filings or press releases.

### How does Panbela Therapeutics differentiate itself from other oncology developers?

Panbela focuses exclusively on synthetic sphingolipid analogs, a mechanism distinct from the dominant approaches in oncology (e.g., immune checkpoint inhibitors, targeted kinase inhibitors). This niche reduces direct competition but also caps pipeline breadth, as sphingolipid pathways remain less validated in clinical settings.

### Is Panbela Therapeutics a public company?

Panbela Therapeutics does not appear on major stock exchanges. Its ownership structure and registration status remain unclear from public records. The firm has not filed an S-1 or disclosed any public trading symbol.

### What clinical trials has Panbela Therapeutics conducted?

The firm's most advanced asset, ivivimal, completed a Phase 2 trial for advanced hepatocellular carcinoma (ClinicalTrials.gov identifier unknown as of 2023). Other preclinical programs target pancreatic and colorectal cancers, but no Phase 1 or Phases 3 trial results have been made public.

### Where is Panbela Therapeutics headquartered?

Panbela Therapeutics lists its headquarters in Waconia, Minnesota, United States. No additional office locations have been disclosed.

### Is there public information about Panbela's team or leadership?

No named executives, scientific advisors, or board members are listed in public filings or on the firm's website. The company has not issued press releases or regulatory filings that identify key personnel as of mid-2025.

## Related profiles

- [Quantified Ventures](https://altss.com/profile/quantified-ventures)
- [Orion Service Group](https://altss.com/profile/orion-service-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/panbela-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology